Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38485927.
- Also identified by DOI 10.1038/s41467-024-46295-8 and PMC identifier 10940300.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Viral fusion proteins facilitate cellular infection by fusing viral and cellular membranes, which involves dramatic transitions from their pre- to postfusion conformations. These proteins are among the most protective viral immunogens, but they are metastable which often makes them intractable as subunit vaccine targets. Adapting a natural enzymatic reaction, we harness the structural rigidity that targeted dityrosine crosslinks impart to covalently stabilize fusion proteins in their native conformations. We show that the prefusion conformation of respiratory syncytial virus fusion protein can be stabilized with two engineered dityrosine crosslinks (DT-preF), markedly improving its stability and shelf-life. Furthermore, it has 11X greater potency as compared with the DS-Cav1 stabilized prefusion F protein in immunogenicity studies and overcomes immunosenescence in mice with simply a high-dose formulation on alum.
Medical subject headings
- Respiratory Syncytial Virus, Human
- Tyrosine
- Respiratory Syncytial Virus Infections
- Respiratory Syncytial Virus Vaccines